Patient-matched dissolving scaffolds that rebuild jaw bone after surgery
TL;DR Graftwright 3D-prints a scaffold shaped to each patient's jaw defect from their CT scan, in a polymer-ceramic blend the body slowly absorbs as new bone grows in. Hospitals and maxillofacial surgeons buy it per case. It goes after a gap Indian implant makers leave open - metal and PEEK implants stay in for life.
When surgeons remove part of a jaw for a tumour, infection or injury, they usually rebuild it with bone taken from the patient's leg or hip, or with a permanent titanium or PEEK implant. Neither is free. You get a second wound and longer surgery, or a foreign body that can get exposed or infected years later.
India saw this at scale after the COVID-19 mucormycosis wave. IIT Madras and a Chennai implant startup supplied 47 free 3D-printed facial implants to survivors and cut surgery time sharply[1]. That project proved the demand and the surgeon interest, but those implants were permanent and never meant to turn into bone.
What it does, in regulatory terms: an implantable, resorbable medical device for bone regeneration. It is a high-risk device under CDSCO's Medical Devices Rules 2017 (likely Class C or D) and needs a manufacturing licence and, without a predicate, a clinical investigation before sale[2]. It carries no living cells and makes no claim to regrow whole organs.
Here's the flow. From a CT scan, Graftwright's engineers design a porous scaffold that fills the defect exactly and the surgeon signs off on screen, then the part is printed in a polycaprolactone and tricalcium phosphate blend, sterilised and shipped within days. Bone grows into the pores while the scaffold slowly dissolves.
The seed promised bioprinted living tissue for organ repair. Nobody has a licensed bioprinted organ, so we pulled it back to the nearest thing that already works in patients. A 2026 case series in Iran used this kind of scaffold in five jaw patients and saw 30–75% new bone fill over 12–18 months, with minor problems in three[3]. Five patients is early evidence, and I wouldn't call it proof.
The patient is usually an oral cancer or trauma survivor. The buyer is the hospital, on the surgeon's recommendation, inside a package that insurers or government schemes may or may not cover. Indian patient-specific titanium implants are already bought per case[4], so the buying habit is there. I couldn't find a public Indian price for resorbable scaffolds.
CDSCO licensing has applied to Class C and D devices since 1 October 2023, so the route is defined, if slow[2]. The Technology Development Board backed an Indian bioceramics firm in September 2026 to commercialise 3D-printed patient-specific calcium phosphate grafts[5], which tells you public funders now see Indian-made bioceramics as worth backing.
There's no public figure for India's resorbable patient-specific scaffold market. The closest signal comes from Pune, where one implant maker reported more than 3,000 patient-specific implants by April 2024, all in titanium, PEEK or PMMA[4]. So surgeons already order custom parts per case. Treat it as adjacent demand and not your market.
A Pune maker sells permanent patient-specific cranial and jaw implants[4]. An Indian bioceramics firm is moving into printed ceramic grafts with TDB funding[5]. A Singapore company sells 3D-printed bioresorbable implants across Asia, Europe, Australia and the Americas, with a global orthopaedics major distributing its craniofacial line[6]. Nobody yet offers a CDSCO-licensed, made-in-India resorbable jaw scaffold designed per patient.
| Difficulty | Very hard (76/100) |
| Starting capital | ₹8–15 Cr |
| Time to launch | 30–48 months |
Printing the part is the easy bit. The hard parts are a clean-room plant with a certified quality system, animal and biocompatibility testing, a clinical investigation with enough patients to convince CDSCO and surgeons, and design turnaround fast enough for cancer surgery dates. Cancer doesn't wait for your print queue.
Yes, and a lot of it. This is a high-risk implant, so nothing gets sold until CDSCO signs off.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI make the call on whether a design is safe to implant. A surgeon and your engineers sign off on every part.
Want to work out the AI layer for Graftwright? Talk to Yash →
Here's what can go south -
I'd only touch this with a biomaterials scientist, a maxillofacial surgeon co-founder and patient capital on the team. It is a poor fit for a software-first founder. Prove two things first - that you can print a scaffold that passes biocompatibility tests and that two hospital ethics committees will host a trial.
Plan for roughly ₹8–15 Cr, much of it going into a clean-room plant, testing and a clinical investigation before any sale.
Yes. It is a high-risk device under the Medical Devices Rules 2017, so you need a CDSCO manufacturing licence and, without a predicate, an approved clinical investigation first.
Yes, but every market treats this as a high-risk implant. Expect a similar path of quality system, clinical data and device approval with your local regulator.
The free Graftwright validation kit has the line-by-line capital breakdown, the effort scoring, the CDSCO licensing and clinical investigation checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for surgeons and hospitals, and 5 assumptions to test. Download the kit →
Thinking about building Graftwright or something close to it? The make-or-break work is planning a clinical investigation that CDSCO and surgeons will both accept, and that's where I can help. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.